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here is a growing interest in the discovery and
development of new therapeutics that will
cure chronic hepatitis B virus (HBV) infection, due to the recent establishment of new cell
culture–based and small animal–based models. These
new systems create unprecedented opportunities to
study the entire viral life cycle and to search for
vulnerabilities that can be exploited for curative purposes. Here, we propose a scientiﬁc pathway that we
believe will lead to the development of curative therapies
for chronic HBV infection and its associated diseases.
HBV is a hepatotropic, noncytopathic, partially
double-stranded DNA virus that replicates by reverse
transcription of a greater-than-genome-length RNA
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and causes acute and chronic necro-inﬂammatory liver
disease (hepatitis), cirrhosis of the liver, liver failure,
and hepatocellular carcinoma (HCC).(1,2) Approximately 2 billion people alive today have been infected
by HBV 250 million of whom are currently chronically
infected.(3,4) Antiviral drugs that suppress viral replication and retard disease progression are available; however, treatment is generally not curative and is lifelong,
expensive, and limited by the extent to which it fails to
reduce the risk of death due to liver disease. A highly
effective protective vaccine is available, leading the
World Health Organization and the National Academies of Science, Engineering, and Medicine to
recently declare that elimination of HBV is possible if

Abbreviations: cccDNA, covalently closed circular DNA; HCC, hepatocellular carcinoma; HBV, hepatitis B virus.
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a curative therapy can be developed to supplement the
protective effect of the vaccine.(3,5,6) This document
introduces the challenge and presents a roadmap for
the discovery of a cure.
Development of a cure for any viral infection requires
a sufﬁciently deep understanding of the virus life cycle
and its interaction with the host to identify vulnerabilities that can be exploited to eradicate the cccDNA from
infected cells. The key word here is “eradicate.” In general, the targetable steps in the HBV life cycle include
entry, uncoating, delivery of the viral DNA genome to
the nucleus, establishment and maintenance of the covalently closed circular DNA (cccDNA) transcriptional
template in the nucleus of the cell, followed by transcription, translation, replication, viral and subviral particle
assembly, transport and release, and the recycling of
cytoplasmic capsid particles to the nucleus to amplify the
intracellular pool of cccDNA. Eradication also requires
engagement of the host immune response to kill infected
cells, to prevent viral spread from any residual infected
cells and to counteract any evasive strategies deployed by
the virus to defeat the host response.
Despite its discovery 50 years ago, most steps in the
HBV life cycle and the nature of its interaction with its
host are only partially understood because the experimental systems required for such experiments have not
been available.(7) Furthermore, despite the ability of
currently available direct-acting antiviral drugs to suppress HBV DNA replication, they are rarely curative
because they do not prevent the establishment or
maintenance of the long-lived HBV cccDNA
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transcriptional template—the stable nuclear form of
the viral genome, which must be eliminated or permanently silenced to achieve a durable HBV cure.(8)
Luckily, experimental systems that permit detailed
analysis of cccDNA biogenesis, homeostasis, and decay;
and all other steps in the viral life cycle were recently
developed.(9) Thus, we are now on the threshold of a
period of exploration that, if focused on eliminating the
cccDNA transcriptional template of the virus, could lead
to a cure of chronic HBV infection, once and for all.
We encourage the scientiﬁc community to focus on
research leading to discovery of a cure for chronic
HBV infection based on these principles, as summarized here and highlighted in Fig. 1:









The surest way to cure HBV is to eliminate or
permanently silence its cccDNA.
The most important impediment to this achievement is our limited understanding of the fundamental molecular mechanisms that control
cccDNA biogenesis, homeostasis, and decay.
Understanding these mysteries is now within
reach, thanks to recent technological advances
that enable definition of these mechanisms.
Vulnerabilities in the cccDNA “life cycle” that are discovered in the course of these studies can be exploited
to develop small molecule and other molecular strategies to eradicate or permanently silence the cccDNA.
Because these studies will explore the unknown,
the outcome, like all great adventures, cannot be
predicted. Thus, we suggest that in addition to
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FIG. 1. HBV life cycle, emphasizing opportunities to suppress viral cccDNA and restore immune control. Host and viral functions
that could be exploited for therapeutic purposes are illustrated, beginning with binding of the virus to the sodium–taurocholate
cotransporting polypeptide receptor on hepatocytes (1), followed by translocation of the nucleocapsid to the nucleus and formation of
cccDNA (2) and synthesis steps (3,4), leading to either egress (6) of newly formed virions or recycling of cccDNA-containing nucleocapsids to the nucleus (7). Opportunities for cccDNA suppression and immune control are categorized as either acting upon the viral
gene products (white boxed text) or acting upon host innate and adaptive immune systems (green boxed text), noting that in many
cases these different pathways overlap. Humoral responses are also indicated (Abs). Orange, red, and brown circles indicate small,
medium, and large hepatitis B surface proteins, respectively; yellow triangle (core protein), blue circle (pol), “X” (x protein), red semicircles, cccDNA and black line, HBV 3.2 kb and subgenomic HBV RNA; 22-nM in diameter spherical and rod-shaped subviral envelope particles and infectious 42-nM virions are also illustrated. The examples of virus life cycle steps and immune modulators are
representative and not comprehensive. Toll-like receptor 3 is shown because it is present in hepatocytes, but other toll-like receptors
may also be exploited therapeutically. Abbreviations: Abs, antibodies; CTLA4, cytotoxic T lymphocyte antigen 4; IFNAR, type 1
interferon receptor; NTCP, sodium–taurocholate cotransporting polypeptide; PD1, programmed death 1; TLR3, Toll-like receptor 3.




approaches that directly target cccDNA, independent approaches that target other vulnerabilities
in the viral life cycle and either indirectly repress
HBV cccDNA or safely establish a curative antiviral immune response be pursued in parallel.
Such projects could include genetic approaches to
cccDNA mutagenesis, epigenetic modification, or
other strategies that can suppress cccDNA transcription (e.g., HBV-targeted antisense and small interfering RNA, HBV X protein inhibition, etc.) or to
prevent its recycling (e.g., capsid inhibitors).

Of course, a vigorous basic and translational research
effort to better deﬁne the nature of the immune
response to HBV in chronically infected patients is also

essential. Ideally, the antibody response would be examined at the single B-cell level to reveal the extent to
which neutralizing antibodies are produced by chronically infected patients and to determine whether patients
who are “cured” of HBV by direct-acting antivirals will
require active immunization to prevent intrahepatic viral
spread from any infected cells that remain after treatment and to protect them from future exposure.
Similarly, the functional and phenotypic characteristics of the HBV-speciﬁc T-cell response must be studied before, during, and after curative treatment to
determine the extent to which it contributes to the
durability or the failure of a given therapeutic strategy.
In addition, a wide variety of immune-based strategies that can induce T cell–mediated elimination of
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HBV-infected cells should be explored, including
diverse approaches including therapeutic immunization, targeted delivery of antiviral effector molecules to
infected cells, T-cell checkpoint blockade of T cell
inhibitory checkpoint pathways, and targeted delivery
of HBV-speciﬁc effector T cells to the HBV-infected
liver by T cell receptor-based or chimeric antigen
receptor (CAR)-T cell technology, etc, should be
explored.
These studies should be iterative, where results from
the clinical work guide the laboratory work and vice versa.
In this way, the immunobiology, number of infected
cells, and other clinical parameters of chronic hepatitis B
as a function of medical intervention can be followed.
We also note that HCC can be a consequence of
chronic hepatitis B. Therefore, to comprehensively address the problems associated with chronic viral hepatitis B,
an improved understanding of the molecular basis of
HCC to guide early detection and treatment is vital. Clinical collaborative networks should also be reinforced and
expanded to allow for evaluation of new early detection
strategies of HCC and therapeutics of HCC and HBV.
It is also important to note that any intervention
that directly or indirectly activates the cytotoxic T-cell
response to HBV could kill all the infected hepatocytes. This would be good if only a few hepatocytes in
a given patient are infected and the functional hepatic
reserve in that patient is robust. On the other hand, it
could be fatal, inducing an acute on chronic liver disease event, if many hepatocytes are infected and
hepatic reserve is tenuous. Thus, if the cytotoxic T-cell
response is activated by any therapeutic intervention, it
must be in a “Goldilocks zone,” where it kills just
enough hepatocytes at just the right rate to clear the
infection without either triggering acute hepatic insufﬁciency or worsening the underlying chronic liver disease. It is imperative, therefore, to do these studies if
we hope to predict how infected patients will respond
immunologically to curative therapy before treatment
begins, keeping in mind that the physician’s ﬁrst
responsibility is primum non nocere, “ﬁrst, do no harm.”
A recent review article from Revill et al. speciﬁed
broad goals for HBV research and has since led to the
establishment of an international coalition of scientists,
clinicians, and stakeholders committed to the elimination of HBV (International Coalition to Eliminate
HBV; http://ice-hbv.org/).(10) Our intention is to support and build upon their effort by adding detail to create a roadmap for policy makers from government and
other funding institutions and for planning long-term
research.
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A cure for hepatitis B is also likely to greatly reduce
morbidity and mortality associated with hepatitis delta
virus infection, end-stage liver disease, and HCC,
although it is appreciated that these clinical problems
deserve a speciﬁc research agenda of their own.
It is clearly important to explore multiple viral gene
products and life cycle steps for intervention opportunities. To date, of all of the candidate approaches
considered, elimination of HBV cccDNA is most
likely to produce a durable cure of chronic HBV
infection, after a ﬁnite course of antiviral therapy. The
extent to which this can be achieved with drugs, biologicals, genetic manipulations, immunomodulation,
etc. is the major question to be answered. While transcriptional silencing of cccDNA may be easier to
achieve than physical cccDNA elimination, it would
probably require lifelong treatment to produce lifelong effects unless it triggers some unpredictable
durable downstream effect like immune-mediated
destruction or noncytolytic elimination of cccDNA
from the infected cells. Thus, a vigorous, comprehensive, adequately funded research effort involving multiple, complementary approaches must be taken, with
the results being shared in the public domain as
quickly as possible.
Luckily, experimental systems that permit detailed
analysis of the cccDNA and other steps in the viral life
cycle are now available to the scientiﬁc community for
these challenges. In our opinion, a concerted discovery
effort that is both encouraged and enabled by governmental and nongovernmental funding agencies can
make a huge difference in the lives of hundreds of millions of people worldwide. Let us not let this chance to
do so much good slip away.
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